Trials / Terminated
TerminatedNCT00304252
Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease
A Phase II, Multicenter, Randomised, Double-blind, Placebo Controlled, Dose Finding Study of Subcutaneously Administered Interferon Beta-1a for Maintenance of Remission in Patients With Crohn's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 192 (planned)
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to determine the safety and efficacy of interferon beta-1a in maintaining remission in patients with Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1a |
Timeline
- Start date
- 2001-11-01
- Completion
- 2003-09-01
- First posted
- 2006-03-17
- Last updated
- 2013-08-06
Locations
5 sites across 5 countries: Germany, Italy, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00304252. Inclusion in this directory is not an endorsement.